Markus Maeurer

Research interests

Publications

• The WHO Global Tuberculosis 2021 Report – not so good news and turning the tide back to End TB

  International Journal of Infectious Diseases · 2022 · 10.1016/j.ijid.2022.03.011

• Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts

  International Journal of Infectious Diseases · 2021 · 10.1016/j.ijid.2021.11.040

• Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial

  Signal Transduction and Targeted Therapy · 2021 · 10.1038/s41392-021-00488-5

• Single-cell landscape of immunological responses in patients with COVID-19

  Nature Immunology · 2020 · https://doi.org/10.1038/s41590-020-0762-x

• Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases

  Frontiers in Immunology · 2020 · 10.3389/fimmu.2020.610300

• Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial

  Signal Transduction and Targeted Therapy · 2020 · 10.1038/s41392-020-00286-5

• Reducing mortality from 2019-nCoV: host-directed therapies should be an option

  The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)30305-6

• Immunological and inflammatory profiles in mild and severe cases of COVID-19

  Nature Communications · 2020 · https://doi.org/10.1038/s41467-020-17240-2

• Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19)

  Cell Death and Differentiation · 2020 · 10.1038/s41418-020-0572-6

• Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies

  The Lancet Infectious Diseases · 2018 · 10.1016/s1473-3099(18)30110-5

• Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers

  The Lancet Infectious Diseases · 2016 · 10.1016/s1473-3099(16)00070-0

• Host-directed therapies for infectious diseases: current status, recent progress, and future prospects

  The Lancet Infectious Diseases · 2016 · 10.1016/s1473-3099(16)00078-5

• Tuberculosis treatment and management—an update on treatment regimens, trials, new drugs, and adjunct therapies

  The Lancet Respiratory Medicine · 2015 · 10.1016/s2213-2600(15)00063-6

• New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects

  The Lancet Infectious Diseases · 2014 · https://doi.org/10.1016/s1473-3099(13)70328-1

• Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review

  The Lancet Respiratory Medicine · 2014 · 10.1016/s2213-2600(14)70033-5

• Rapid point of care diagnostic tests for viral and bacterial respiratory tract infections—needs, advances, and future prospects

  The Lancet Infectious Diseases · 2014 · 10.1016/s1473-3099(14)70827-8

• Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test

  The Lancet Infectious Diseases · 2013 · https://doi.org/10.1016/s1473-3099(13)70008-2

• Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts

  The Lancet Infectious Diseases · 2013 · 10.1016/s1473-3099(13)70015-x

• Drug-resistant tuberculosis: time for visionary political leadership

  The Lancet Infectious Diseases · 2013 · 10.1016/s1473-3099(13)70030-6

• Tuberculosis biomarkers discovery: developments, needs, and challenges

  The Lancet Infectious Diseases · 2013 · 10.1016/s1473-3099(13)70034-3

• Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation

  Haematologica · 2013 · 10.3324/haematol.2013.087338

• Tuberculosis Diagnostics and Biomarkers: Needs, Challenges, Recent Advances, and Opportunities

  The Journal of Infectious Diseases · 2012 · 10.1093/infdis/jir860

• Antigen-processing machinery breakdown and tumor growth

  Immunology Today · 2000 · https://doi.org/10.1016/s0167-5699(00)01692-3

• Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

  Journal of Clinical Investigation · 1996 · 10.1172/jci118958

• Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes.

  The Journal of Experimental Medicine · 1995 · 10.1084/jem.181.1.363

Current projects

No projects listed.